Capsid, envelope, and nonvirion-associated soluble components of type I and type 2 herpes simplex virus (HSV) were obtained from infected monolayer cell cultures and used as complement fixation (CF) antigens. Capsids were prepared by treatment of cells with the nonionic detergent Nonidet-P40, envelope material by treatment of virions with ether and high pH, and soluble components were obtained from culture fluids of untreated cells. Serological studies with experimental anti-herpesvirus sera indicate that these serotypes share cross-reacting envelope, capsid, and soluble antigens with each other and with herpesvirus B but not with varicella virus. In addition, animals immunized with crude HSV preparations contain high levels of CF antibody (1: 32 to 1: 64) to soluble antigens, whereas sera from humans who have experienced natural infection contain low levels of antibody (<1:8) to this antigen. Further testing with reference, capsid, and envelope antigens indicates that antibody levels to reference and capsid antigens are about the same in sera from healthy humans, whereas antibody to the envelope is decidedly lower in these sera. Herpes convalescent-phase sera contain higher levels of antibody to reference and envelope antigens than to capsid antigen.
Preliminary studies in this laboratory indicated that cell cultures infected with either herpes simplex virus (HSV) strain VR #3 (type 1) or MS (type 2) produced two complement-fixing (CF) antigens. One was associated with the virus and the other with a soluble viral product present in cell-free culture fluids. Sera of animals immunized with crude virus preparations had high levels of CF antibody to both antigens, whereas sera from humans who had experienced natural infection had low levels of antibody to soluble antigens and high levels to virus-associated antigen. The latter was true although the virus-associated antigens of VR #3 contained large numbers of both enveloped and nonenveloped particles; similar preparations of MS contained predominantly nonenveloped particles. In addition, other data have indicated that HSV nonenveloped particles (capsids) are weakly antigenic (9) . These findings suggest that sera of animals immunized with crude virus material and humans with a history of herpetic infection may have different CF antibody levels to separate HSV-specific components or products.
In this study, the preparation and CF activity of type 1 and type 2 herpes soluble products, particles deenveloped by detergent treatment (capsid antigen), and envelope material are reported. The antigenic relationship between these subviral components, as demonstrated by CF in reactions with human anti-HSV sera and experimental antisera to HSV, varicella virus (VV), and herpesvirus B (HVB), is described.
MATERIALS AND METHODS Virus. The VR # 3 strain of type 1 (12) and the MS strain of type 2 (4) HSV were used to prepare HSV antigens and antisera. HVB was obtained from Robert Hull, Eli Lilly & Co., Indianapolis, Ind. W CF antigen was prepared as described previously (5) .
Virus propagation. HSV strains were grown in primary rabbit kidiney (PRK) or continuous African green monkey (VERO) monolayer cultures in 32-oz (approximately 1 liter) glass prescription bottles. Culture medium consisted of a modified (6) Eagle's essential medium with 10% calf serum. The same medium with or without 2%r serum was used to propagate virus. Monolayer cultures were inoculated with a multiplicity of 5 to 10 and incubated for 48 hr at 35 C. HVB was propagated only in PRK monolayer cultures.
Capsid HSV CF antigens. Capsid CF antigens of strains VR §#3 and MS consisted of preparations of particles from which the viral envelope was dissociated by detergent treatment. Maintenance media were decanted from infected cultures, and the cells were 248 on October 28, 2017 by guest http://iai.asm.org/ Downloaded from CF ANTIGENS OF HERPES SIMPLEX VIRUS scraped into 10 ml of 2.5% Nonidet P-40 (NP-40) in distilled water per culture. Cells were sonically treated for 10 min in 2-oz (approximately 60 ml) Boston round bottles with a 10-kc Raytheon sonic oscillator and then incubated for 1 hr at 37 C. The material was then filtered through Nalgene membrane filters of 0.45 and 0.20 ,um porosity. Deenveloped particles in the final filtrate were freed of NP-40 and dissociated envelope components by layering over a 30% (w/v) sucrose cushion and centrifuging for 45 min at 35,000 rev/min in a Spinco SW40 rotor. The pellet resulting from this centrifugation contained the partially purified HSV deenveloped particles used in these studies. Control antigens were prepared from uninfected cell cultures treated the same as infected cultures. Before use, each preparation was monitored by electron microscopy for the presence of enveloped particles.
Envelope HSV CF antigen. Envelope CF antigens of strains VR # 3 and MS consisted of viral material extracted with ether and high pH. Infected cells were scraped into the maintenance media, and the suspension was sonically treated for 10 min as described above. The sonicate was centrifuged for 1 hr at 30,000 rev/min in a no. 30 Spinco rotor. The pellet, which contained virions, from this centrifugation was resuspended in 3 ml of distilled water per culture and treated with an equal volume of diethyl ether at 4 C for 30 min. Ether was removed by bubbling nitrogen through the treated suspension. The ether-treated virus preparation was then dialyzed at 4 C for 24 hr against 0.85% NaCl buffered at pH 10.5 with 0.05 M glycine-NaOH. The dialyzed material was layered onto a 35% sucrose cushion and centrifuged for 1 hr at 30,000 rev/min in an SW40 Spinco rotor to separate the envelope material from capsids or capsids with envelope remnants. The supernatant fluid from this centrifugation contained envelope material. It was collected and dialyzed against Veronal buffer before use in CF tests.
Soluble HSV CF antigen. Soluble CF antigens of strains VR # 3 and MS were prepared from the fluid phase of virus propagated in serum-free maintenance media. The media were decanted and centrifuged at 30,000 rev/min for 1 hr in a no. 30 Spinco rotor. The supernatant fluid from this centrifugation was concentrated approximately 25-fold by pervaporation, and then dialyzed at 4 C against Veronal buffer, pH 7.3. The dialysate was further purified by layering it onto a 10 to 30% (w/v) sucrosegradient and centrifuging it at 25,000 rev/min for 14 hr in an SW40 Spinco rotor. The soluble CF antigen remained in fractions at the top of the gradient. These were collected and dialyzed against Veronal buffer.
Sera. Antisera to HSV capsid CF antigens were prepared in guinea pigs by immunization with antigen prepared from infected PRK cells. They were injected intramuscularly with 1 ml of antigen derived from three monolayer cultures mixed with an equal amount of Freund's incomplete adjuvant. After the initial injection, two weekly injections of 1 ml of antigen in saline were given. The animals were bled 10 days after the final injection.
Antisera to enveloped HSV were prepared in guinea pigs by immunization with strains VR #3 and MS which were partially purified by equilibrium centrifugation in CsCl density gradients and rate/zonal centrifugation in sucrose gradients. Control antisera were prepared by using uninfected tissue culture treated the same as virus-infected cultures. The immunization schedule was the same as that used in preparing antisera to capsid antigen.
HVB antisera were prepared in New Zealand White FIG. 1. Electron micrograph of typical herpesvirus negatively stained with uranyl acetate. E, envelope; N, nucleocapsid. X 111,000.
rabbits by intramuscular injection with BPL (betapropiolactone)-treated virus in Freund's incomplete adjuvant. Two weekly injections of BPL-treated virus in adjuvant were followed by one injection of untreated infected PRK tissue culture material. The animals were bled 2 weeks after the final injection.
Antisera prepared in rabbits against crude preparations of HSV strains US (type 1) and L-2 (type 2) were obtained from John Stewart, Center for Disease Control (CDC), Atlanta, Ga. Anti-varicella virus serum was prepared as described previously (5) .
Human sera used in these studies were obtained from the CDC serum bank or from specimens submitted to CDC for serological testing. Herpes convalescent-phase sera were collected from humans with nongenital herpes infection. Electron microscopy. Specimens were prepared by the pseudoreplica technique (14) Data presented in Table 3 show the complete range of CF titers found in a group of normal sera tested against HSV (VR # 3) reference, capsid, envelope, and soluble antigens. The sera were chosen from control sera on file in the CDC serum bank and included sera from males and females, ages 7 to 71, from various geographical herpesviruses (1, 10) . The selective action of the detergent in dissociating the envelope of type 1 and type 2 herpes made it possible to obtain subviral CF antigen of these serotypes in sufficient quantities for serological studies. Electron microscopy revealed that detergent-treated herpes preparations contain only deenveloped forms of the virus. The particles were apparently not significantly altered either morphologically or antigenically; they retained the characteristic icosahedron configuration of herpes capsids, elicited CF antibody production in immunized animals, and actively fixed complement in reactions with human sera containing HSV antibody.
Sufficient quantities of antigenically active envelope material for serological studies were obtained by treatment of HSV with ether and high pH. Neither ether nor high pH, separately or combined, completely deenveloped the particles nor destroyed the structural integrity of the capsid. Envelope material was easily separated from capsids and capsids with envelope remnants by ultracentrifugation through sucrose. Envelope material derived from NP-40-treated HSV was not active in the CF test. The detergent apparently associates tenaciously with viral lipoprotein and, even in small quantities, inactivates complement.
Envelope antigens of HSV were not reactive in CF tests with anticapsid sera, indicating that the capsids used for immunization contained no antigenically active envelope components and that the envelope antigens contained no antigenically active capsid components. These findings confirmed results of electron microscopy which showed no capsids present in envelope antigen preparations. Envelope antigens were weakly reactive or nonreactive with antisera to purified virus. In this regard it is possible that CsCl altered the antigenic property of the HSV envelopes. Electron microscopy revealed that purified virus preparations used for immunization contained enveloped virus but that many particles had distorted envelopes.
Nonviral-associated CF antigens of both herpes types were readily obtained from cell-free culture fluids. They were physically separable from particulate material by ultracentrifugation and were active in CF and indirect hemagglutination (13) tests but contained no virions or capsids. These CF antigens are probably the same "soluble" antigens as previously described by others in fluids of disrupted VR # 3-infected cell cultures (12) . However, they do not appear to be virion precursors because they failed to react in CF with experimental antiserum to partially purified enveloped or deenveloped particles. Capsid, envelope, and soluble antigens were all rfarkedly reactive with antisera to crude type 1 and type 2 HSV. These antisera contained significant amounts of antibody to all HSV antigens tested probably because they were prepared in a susceptible host with high-titered infectious virus, which had received no deleterious treatment such as CsCl centrifugation or ether treatment. It was noted that titers of these antisei a were consistently higher when tested with homologous capsid, envelope, and soluble antigens than when tested with heterologous antigens of similar origin.
The finding that experimental antitype 1 capsid sera were more cross-reactive than similar preparations of type 2 herpes is somewhat at variance with neutralization tests which indicate that type 1 serum is better for typing isolates (8 lescing from a recent herpetic infection. The range of antibody titers to these subviral components was of the same magnitude (-1 :32) in both groups, but the latter group had a higher titer to reference antigen which contained virions, capsids, and soluble components. This finding suggests that CF antibody to the capsid component is longer lasting than that to viral envelope components or soluble antigens and is probably responsible for a large portion of the antibody detected in routine CF tests for herpes. This interpretation is supported by the findings of others which indicate that CF antigen appears in infected cells before virus (3) and that capsids combine with early 19S and late 7S but not with late 19S or early 7S antibody (7). Data of Nii et al. (9) which indicate that the capsid of HSV may be poorly antigenic were probably derived from experiments with sera which contained low levels of late 7S antibody. The preparations of capsids also fail to produce neutralizing antibody probably because envelope components are not present. Concomitantly, it is a priori not illogical to assume that antibody to a virus which is largely quiescent and requires an envelope for infectivity would be directed primarily against an internal viral component rather than an envelope or soluble component produced on active infection. Consonant with these observations, our data show that CF antibody to the HSV envelope is increased in convalescent sera relative to antibody levels in sera from healthy individuals with less recent exposure to herpes.
Testing of sera from healthy individuals with past exposure to herpes with reference, capsid, envelope, and soluble antigens showed that levels of antibody to reference and capsid antigens were approximately the same, whereas antibody to the envelope was at a lower level, and antibody to soluble antigen was 1:8 or less in all sera tested. The finding that reference antigen detected higher levels of antibody in herpes convalescent sera than did capsid antigen indicated that the envelope of HSV plays a major role in host antibody response to active herpes infection. This was confirmed by testing herpes convalescent sera against envelope antigen. These sera showed rises in antibody levels to the HSV envelope antigen. These 
